Rhythm Pharmaceuticals, Inc. RYTM 深 滬
等待開盤 09-08 09:30:00 美东时间
102.74
-2.150
-2.05%
華盛通- 最 高105.71
- 今 開103.53
- 成交量 46.69万股
- 最 低 101.25
- 昨 收 104.89
- 總市值 70.74亿
- 52周最高 122.20
- 市盈率 靜 --
- 換手率 0.68%
- 52周最低 74.50
- 委 比 -79.12%
- 總股本 6885.21万
- 歷史最高 122.20
- 量 比 1.03
- 振 幅 4.25%
- 歷史最低 3.04
- 每 手 1
- 風險率 9.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Hold rating and announces Price Target of $120.
08-28 20:58
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shares are trading higher on Wednesday. On Tuesday, the company said the UK is expanding its marketing authorization for Imcivree (setmelanotide). Read Also: Why Is Rhythm Pharma Stock Jumping Today? RYTM Stock Rises On Expanded IMCIVREE Marketing Authorizat...
08-13 01:18
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Citizens analyst Jonathan Wolleben maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Market Outperform and raises the price target from $155 to $160.
08-05 23:11
财报速睇 | Rhythm Pharmaceuticals, Inc. 2026财年Q2营收0.71亿美元，同比增长46.8%；归母净利润亏损0.50亿美元，同比亏损扩大5.0%
华盛资讯8月5日讯，Rhythm Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.71亿美元，同比增长46.8%，归母净利润亏损0.50亿美元，同比亏损扩大5.0%。
08-05 09:07
财报速睇 | Rhythm Pharmaceuticals, Inc. 2026财年Q2营收0.71亿美元，同比增长46.9%；归母净利润亏损0.50亿美元，同比亏损扩大5.0%
华盛资讯8月4日讯，Rhythm Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收0.71亿美元，同比增长46.9%，归母净利润亏损0.50亿美元，同比亏损扩大5.0%。
08-04 20:02
Rhythm Pharmaceuticals Q2 EPS $(0.73) Beats $(0.82) Estimate, Sales $71.255M Beat $67.277M Estimate
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.82) by 10.98 percent. This is a 2.67 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $71.255 ...
08-04 19:07
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
JP Morgan analyst Priyanka Grover initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight rating and announces Price Target of $145.
07-27 19:18
